Search Results for "Mp 513 Metformin Monotherapy Type 2 Diabetes"
Matching Channels
2.8 million people in the UK have been diagnosed with diabetes in the UK and a further 850,000 people are undiagnosed. Diabetes is characterized by high blood glucose levels, resulting from a prob...
Actos, produced by Takeda Pharmaceuticals North America, Inc netted $2.5m in sales in 2009, the 9th highest in the world. Actos is a type of thiazolidinediones, acting to increase sensitivity to I...
Matching News
Diabetes: Add-on to metformin in T2DM—linagliptin or glimepiride?
Clinicians are responsible for selecting a suitable second-line treatment for patients with type 2 diabetes mellitus when metformin monotherapy fails. New evidence could aid clinicians in deciding bet...
Add-on to metformin in T2DM—linagliptin or glimepiride?
Clinicians are responsible for selecting a suitable second-line treatment for patients with type 2 diabetes mellitus when metformin monotherapy fails. New evidence could aid clinicians in deciding bet...
Youths with type 2 diabetes benefit from dual therapy
Combination therapy, with metformin plus a glitazone, achieves better glycaemic control than metformin alone in children and adolescents with type 2 diabetes (New England Journal of Medicine 2012;366...
Combination therapy for youth with type 2 diabetes
A combination of 2 diabetes drugs, metformin and rosiglitazone (Avandia, GlaxoSmithKline), was more effective in treating youth with recent-onset type 2 diabetes than metformin alone, a study fund...
Metformin cuts cardio events in high-risk type 2 diabetes
(HealthDay)—Metformin therapy significantly reduces cardiovascular events in high-risk patients with type 2 diabetes compared to treatment with glipizide, according to a study published online Dec....
Janssen seeks canagliflozin/metformin combo OK in Type II diabetes
Janssen Research & Development is seeking the US FDA's OK to market a fixed-dose combination of canagliflozin and immediate-release metformin as a treatment for patients with Type II diabetes, the c...
[Comment] Type 2 diabetes: which drug as add-on to metformin?
Type 2 diabetes is a progressive disease defined by hyperglycaemia and is associated with hypertension, dyslipidaemia, and an increased risk of cardiovascular events in most patients. The stepwise app...
Imeglimin beneficial as add-on to metformin in T2DM
(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and...
Matching PubMed Articles
The effects of sulfonylureas and metformin on outcomes of cardiovascular disease (CVD) in type 2 diabetes are not well-characterized.
Metformin is widely accepted as first-line pharmacotherapy for patients with type 2 diabetes mellitus when glycemic control cannot be achieved by lifestyle interventions alone. However, uncertainty ex...
Abstract Objective: To document the extent to which drug naïve patients with diabetes continued newly initiated metformin monotherapy, and who subsequently experienced primary failure or therapeutic...
Vildagliptin: a review of its use in type 2 diabetes mellitus.
Vildagliptin (Galvus®, Jalra®, Xiliarx®) is an orally administered dipeptidyl peptidase-4 (DPP-4) inhibitor. In patients with type 2 diabetes mellitus, vildagliptin 50 mg twice daily is indicated...
PURPOSE: To determine guideline conformity of initiation of oral hypoglycemic (OH) treatment for type 2 diabetes in Austria; to study patient and prescriber correlates of recommended initiation with m...
